# TYBR Health

> TYBR Health is a Houston medical device company commercializing the B3 GEL System, a bioresorbable, collagen-based extracellular matrix hydrogel applied during surgery to protect healing tendons and surrounding soft tissues. Its distinction combines flowable delivery, blue coloring for visibility, and a temporary conforming barrier. FDA-cleared in June 2025, it announced first U.S. clinical use in January 2026 and a $30 million Series A in July 2026.

- **Founded:** 2020
- **Headquarters:** Houston, United States
- **Founders:** Tim Keane (Co-founder and CEO), P. Alex Smith (Co-founder and CTO)
- **Products:** B3 GEL System
- **Notable:** FDA 510(k) clearance K250109 on June 6, 2025., Enrollment of first patients in an Australian multicenter tendon-tenolysis study announced September 4, 2025., Company-affiliated preclinical ECM hydrogel study published in Science Translational Medicine on October 8, 2025.

## Products & services

- **B3 GEL System** — FDA-cleared flowable, bioresorbable collagen-based ECM tissue protector with blue coloring and a controlled-delivery applicator. Cleared for management and protection of tendon injuries without substantial loss of tendon tissue, and surrounding tissues such as skeletal muscle and ligament. FDA summary states degradation within 30 days.

## Achievements

- FDA 510(k) clearance K250109 on June 6, 2025.
- Enrollment of first patients in an Australian multicenter tendon-tenolysis study announced September 4, 2025.
- Company-affiliated preclinical ECM hydrogel study published in Science Translational Medicine on October 8, 2025.
- First U.S. clinical use announced January 5, 2026.
- $30 million Series A announced July 21, 2026.

## Latest updates

- **2026-07** — Announced $30 million Series A co-led by Vensana Capital and Mutual Capital Partners; Greg Banker and Liz Todia Zambory join the board. Funds target commercial expansion, broader indications, and clinical studies.
- **2026-01** — Appointed Jeff Tyber to the board on January 12, bringing orthopedic medical device operating experience.
- **2026-01** — Announced first U.S. B3 GEL clinical use on January 5, performed by Dr. Hanna Tammam in Lubbock.

## Links

- Website: https://www.tybrhealth.com/
- LinkedIn: https://www.linkedin.com/company/tybr-health
- Instagram: https://www.instagram.com/b3gel_tybrhealth/

---

Profile page: https://yespress.io/tybr-health
Published by YesPress — https://yespress.io
Last updated: 2026-10-04